Table 3.
Details of recurrent patients and their local-regional failures
| |
|
|
|
Dose–volume histograms statistics to recurrence volume |
|
||||
|---|---|---|---|---|---|---|---|---|---|
| No. | Stage | Site of relapse | Location of the recurrence volume | Vrecur (cc) | Dmean (Gy) | Dmin (Gy) | Dmax (Gy) | V 95% (%) | Type of relapse a |
| 1 |
T4N3b |
Local |
CTV |
13.9 |
69.9 |
48.5 |
75.2 |
97.9 |
In-field |
| |
|
Regional |
CTV |
2.7 |
68.9 |
64.6 |
71.3 |
100 |
In-field |
| 2 |
T4N1 |
Local |
Marginal to CTV |
10.5 |
70 |
51.5 |
77 |
94.3 |
marginal |
| 3 |
T4N0 |
Local |
CTV |
32.9 |
70.9 |
37.6 |
75.4 |
97.7 |
In-field |
| 4 |
T3N3b |
Local |
Marginal to CTV |
13.9 |
62.1 |
11.8 |
74.1 |
74.7 |
marginal |
| |
|
Regional |
CTV |
3.6 |
67.5 |
63.9 |
71.9 |
100 |
In-field |
| 5 |
T2N1 |
Local |
CTV |
15.1 |
67.6 |
60 |
71.2 |
100 |
In-field |
| 6 |
T1N0 |
Local |
CTV |
10.2 |
65.1 |
53.3 |
71.7 |
100 |
In-field |
| 7 |
T3N3b |
Local |
CTV |
2.2 |
70 |
63 |
76.8 |
100 |
In-field |
| |
|
Regional |
Outside CTV |
8.4 |
14.2 |
11.2 |
37.7 |
- |
outside |
| 8 |
T3N1 |
Local |
GTV |
10.6 |
73.5 |
69.1 |
76.3 |
100 |
In-field |
| |
|
Regional |
CTV |
5.5 |
69.6 |
65.9 |
73.6 |
100 |
In-field |
| 9 |
T4N0 |
Local |
GTV |
9.3 |
72 |
61.8 |
74 |
99.2 |
In-field |
| 10 |
T3N2 |
Local |
CTV |
15.2 |
71.9 |
63.3 |
77.3 |
100 |
In-field |
| 11 |
T4N1 |
Local |
CTV |
8 |
72.1 |
66 |
73.8 |
100 |
In-field |
| 12 |
T4N3b |
Regional |
- |
- |
- |
- |
- |
- |
- |
| 13 |
T3N2 |
Regional |
CTV |
20.6 |
67.8 |
51.2 |
72.6 |
99.6 |
In-field |
| 14 |
T2N1 |
Regional 1 |
Outside CTV |
3.6 |
45.3 |
34.6 |
56.7 |
- |
outside |
| |
|
Regional 2 |
Marginal to CTV |
12.6 |
53.4 |
20.6 |
66.7 |
32.5 |
marginal |
| |
|
Regional 3 |
Outside CTV |
2.7 |
54.2 |
46.6 |
61.4 |
19.1 |
outside |
| 15 |
T3N2 |
Regional |
- |
- |
- |
- |
- |
- |
- |
| 16 |
T3N3b |
Regional |
CTV |
4.2 |
66.5 |
61.3 |
69.3 |
100 |
In-field |
| 17 |
T1N2 |
Regional |
GTV |
2.2 |
70.1 |
67.9 |
72.4 |
100 |
In-field |
| 18 |
T3N3b |
Regional 1 |
- |
- |
- |
- |
- |
- |
- |
| Regional 2 | CTV | 22.2 | 65.6 | 51.4 | 73 | 98.8 | In-field | ||
CTV clinical target volume, GTV gross tumor volume; V95%=% of volume of failure receiving at least 95% of prescribed total dose, Vrecur the recurrent tumor volume.
aIn-field refers to 95% of the recurrence volume receiving more than 95% of the prescribed dose. Marginal refers to 20–95% of the recurrence volume receiving 95% of the prescribed dose. Outside refers to less than 20% of the the recurrence volume receiving 95% of the prescribed dose.